A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Na(v)1.7 sodium channels are crucial for pain signaling, particularly in inflammatory and neuropathic pain conditions.
• Gain-of-function mutations in Na(v)1.7 are associated with inherited erythromelalgia (IEM), a severe pain disorder.
• Previous research indicates a significant role for Na(v)1.7 in nociception and sympathetic nervous system function.

Observation:

• A novel mutation, V400M, in the Na(v)1.7 gene was identified in a three-generation Canadian family with IEM.
• Electrophysiological studies revealed that the V400M mutation alters channel activation, deactivation, and inactivation properties, leading to neuronal hyperexcitability.
• Patients in the family experienced pain relief with carbamazepine (CBZ) treatment.

Findings:

• Whole-cell patch-clamp analysis confirmed that the V400M mutation in Na(v)1.7 channels causes abnormal electrical activity in dorsal root ganglia neurons.
• Carbamazepine (CBZ), at therapeutic concentrations, selectively normalized the altered voltage-dependent activation and inactivation of the mutant Na(v)1.7 channels.
• CBZ did not affect the properties of wild-type Na(v)1.7 channels, indicating a specific effect on the mutated form.

Implications:

• The findings demonstrate that carbamazepine (CBZ) can effectively normalize the function of mutant Na(v)1.7 channels in patients with inherited erythromelalgia (IEM).
• This study provides a mechanistic explanation for the therapeutic response to CBZ in this kindred, highlighting the drug's selective action on the mutated channel.
• Functional and pharmacological studies of ion channels offer valuable insights into the pathophysiology of hereditary pain disorders and guide therapeutic strategies.